MindMed Rebrands to Definium Therapeutics as Three Phase 3 Readouts Expected in 2026

MindMed announced it has rebranded to Definium Therapeutics and outlined timelines for three Phase 3 Part A topline readouts for DT120 ODT in 2026. The release also noted plans for a Phase 3 initiation, an analyst day in Q2 2026, and that statements are forward-looking and subject to risks.

MindMed announced a corporate name change to Definium Therapeutics and published a schedule for its late-stage psychiatry development program. The company reported that several Phase 3 topline Part A readouts for DT120 ODT are expected in 2026 and outlined plans for further study starts and public engagement. The announcement included a standard forward-looking information statement and listed risks and uncertainties that could affect its plans. Financial, regulatory and clinical factors were highlighted as possible influences on future results. Key details: - The company reported it has rebranded from MindMed to Definium Therapeutics. - The company announced an anticipated topline Part A readout for the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD) in the second quarter of 2026. - The company announced an anticipated topline Part A readout for the Phase 3 Panorama study of DT120 ODT in GAD in the second half of 2026. - The company announced an anticipated topline Part A readout for the Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD) in mid-2026. - The company stated plans to initiate the Phase 3 Ascend study of DT120 ODT in MDD in mid-2026, expects to host an analyst day in the second quarter of 2026, and anticipates initial Phase 2a data for DT402 in autism spectrum disorder in 2026. - The release noted these are forward-looking statements and listed risk factors including a history of negative cash flows, limited operating history, potential need for additional capital, regulatory and Drug Enforcement Administration scheduling risks, clinical study and research risks, and intellectual property considerations. Summary: The company rebranded and set timelines for multiple late-stage clinical milestones in 2026, including three Phase 3 Part A topline readouts and planned study starts and events. The announcement was accompanied by standard forward-looking disclosures and a list of financial, regulatory and clinical risks that could affect outcomes. Upcoming milestones include the Voyage, Panorama and Emerge Part A readouts, the planned Ascend initiation, and an analyst day in the second quarter of 2026.